192 related articles for article (PubMed ID: 18183589)
1. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
[TBL] [Abstract][Full Text] [Related]
2. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
Ayan D; Maltais R; Roy J; Poirier D
Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
[TBL] [Abstract][Full Text] [Related]
3. New development in intracrinology of breast carcinoma.
Sasano H; Suzuki T; Nakata T; Moriya T
Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
[TBL] [Abstract][Full Text] [Related]
4. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
[TBL] [Abstract][Full Text] [Related]
5. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
[TBL] [Abstract][Full Text] [Related]
6. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
7. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
8. siRNA-based breast cancer therapy by suppressing 17β-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo.
Li F; Zhu Z; Xue M; He W; Zhang T; Feng L; Lin S
Drug Des Devel Ther; 2019; 13():757-766. PubMed ID: 30863015
[TBL] [Abstract][Full Text] [Related]
9. Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1.
Aka JA; Calvo EL; Lin SX
Mol Cell Endocrinol; 2017 Jan; 439():175-186. PubMed ID: 27544780
[TBL] [Abstract][Full Text] [Related]
10. Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestosterone constitute major and concerted players in ER+ breast cancer cells.
Zhang CY; Wang WQ; Chen J; Lin SX
J Steroid Biochem Mol Biol; 2015 Jun; 150():24-34. PubMed ID: 25257817
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Brozic P; Lanisnik Risner T; Gobec S
Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
[TBL] [Abstract][Full Text] [Related]
12. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
Ngueta AD; Roy J; Maltais R; Poirier D
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677690
[TBL] [Abstract][Full Text] [Related]
13. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
14. 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.
Aka JA; Mazumdar M; Chen CQ; Poirier D; Lin SX
Mol Endocrinol; 2010 Apr; 24(4):832-45. PubMed ID: 20172961
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of 17β-hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model.
Xanthoulea S; Konings GFJ; Saarinen N; Delvoux B; Kooreman LFS; Koskimies P; Häkkinen MR; Auriola S; D'Avanzo E; Walid Y; Verhaegen F; Lieuwes NG; Caiment F; Kruitwagen R; ; Romano A
Cancer Lett; 2021 Jun; 508():18-29. PubMed ID: 33762202
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
17. Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
Chetrite GS; Ebert C; Wright F; Philippe JC; Pasqualini JR
J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):51-6. PubMed ID: 10215037
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Li S; Lévesque C; Geng CS; Yan X; Labrie F
Breast Cancer Res Treat; 1995 May; 34(2):147-59. PubMed ID: 7647332
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
20. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
